Hydroxychloroquine Modulates the Progression of Experimentally Induced Benign Prostatic Hyperplasia in Rats via Targeting EGFR/ERK/STAT3 and AR/FOXO1/TRAIL Pathways: Computational and In Vivo Studies

    June 2025 in “ Scientific Reports ”
    Walaa H. El-Maadawy, Ehab Hafiz, Samer A. Tadros, Sally A. Fahim, Haidy M. Ebrahim, Marwa A. Fouad, Yasmin M. Attia
    New to Finasteride? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary In this study on testosterone-induced benign prostatic hyperplasia in rats, hydroxychloroquine significantly reduced prostate-related markers and enhanced therapeutic effects when combined with finasteride, suggesting potential as a new treatment approach.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    This study investigates the therapeutic potential of hydroxychloroquine (HCQ) in treating benign prostatic hyperplasia (BPH) in rats, highlighting its ability to reduce prostate weight, PSA levels, and pro-inflammatory cytokines, while improving tissue histology. HCQ modulates BPH progression by targeting the EGFR/ERK/STAT3 and AR/FOXO1/TRAIL pathways, promoting apoptosis and reducing inflammation. The combination of HCQ with finasteride (Fin) enhances these effects. Molecular docking shows HCQ's strong interactions with key proteins involved in BPH, suggesting it as a promising treatment strategy either alone or with Fin.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results